Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission follo...

Update Il y a 4 ans
Reference: NTR2086

Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77)

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract


Inclusion criteria

  • Non Hodkin's lymfoma (NHL), B-Cell lymphoma

Links